A key epigenetic mark can block the binding of an important gene regulatory protein, and therefore prohibit the gene from being turned off, a new UNSW study in CRISPR-modified mice—published this month in Nature Communications —has shown.

The study has implications for understanding how epigenetics works at a molecular level—and down the track, the scientists hope the research will help them to investigate new treatments for blood disorders.

“Epigenetics looks at how non-permanent, acquired chemical marks on DNA determine whether or not particular genes are expressed,” study leader and UNSW Professor Merlin Crossley says.